middl
east
respiratori
syndrom
mer
viral
respiratori
infect
rang
asymptomat
infect
sever
pneumonia
caus
novel
coronaviru
name
middl
east
respiratori
syndrom
coronaviru
merscov
coronavirus
famili
viral
pathogen
could
caus
anim
human
diseas
merscov
close
relat
sever
acut
respiratori
syndrom
coronaviru
sarscov
differ
lineag
object
chapter
describ
epidemiolog
virolog
clinic
manifest
manag
prevent
mer
septemb
end
may
world
health
organ
notifi
laboratoryconfirm
case
merscov
infect
countri
associ
death
result
case
fatal
rate
saudi
arabia
major
report
countri
total
number
case
death
case
fatal
rate
tabl
world
health
organ
mar
viru
first
isol
june
respiratori
specimen
saudi
patient
jeddah
saudi
arabia
present
sever
pneumonia
progress
acut
respiratori
distress
syndrom
ard
renal
failur
multiorgan
failur
eventu
lead
death
zaki
et
al
week
patient
recent
histori
travel
unit
kingdom
uk
august
case
across
three
hospit
seven
death
case
fatal
rate
payn
et
al
smaller
outbreak
continu
occur
although
number
patient
magnitud
outbreak
less
compar
earlier
year
presum
due
better
infect
control
practic
earlier
identif
case
transmiss
merscov
human
occur
animaltohuman
transmiss
humantohuman
transmiss
commun
addit
nosocomi
transmiss
merscov
occur
frequent
transmiss
describ
uptod
occur
resid
travel
arabian
peninsula
trace
contact
patient
histori
recent
travel
arabian
peninsula
anim
seem
play
import
role
transmiss
merscov
earlier
studi
suggest
bat
might
potenti
reservoir
merscov
hypothesi
base
close
proxim
merscovphylogeneticallyto
tylonycteri
bat
coronaviru
tybatcov
pipistrellu
bat
coronaviru
pibatcov
woo
et
al
studi
saudi
arabia
phylogenet
merscov
ident
short
gene
segment
detect
fecal
sampl
one
captur
bat
near
home
laboratoryconfirm
merscov
patient
howev
live
merscov
never
recov
bat
studi
need
establish
role
bat
transmiss
human
includ
larger
surveil
studi
full
viral
genom
sequenc
epidemiolog
seem
unlik
bat
direct
sourc
human
case
sinc
none
communityacquir
laboratoryconfirm
mer
case
clear
bat
exposur
dromedari
camel
thought
host
merscov
direct
contact
dromedari
camel
within
day
prior
infect
identifi
independ
risk
factor
mer
gossner
et
al
camelhuman
transmiss
also
suggest
previous
healthi
man
jeddah
saudi
arabia
admit
intens
care
unit
icu
sever
mer
pneumonia
die
day
admiss
patient
own
herd
camel
use
visit
daili
day
prior
admiss
four
nine
camel
sick
nasal
discharg
week
prior
patient
onset
symptom
patient
signific
contact
camel
excret
respiratori
specimen
patient
one
camel
show
ident
merscov
full
genom
sequenc
moreov
serum
antibodi
merscov
posit
patient
camel
camel
seroposit
preced
patient
seroposit
suggest
direct
transmiss
camel
patient
larg
crosssect
studi
saudi
arabia
identifi
merscov
infect
patient
histori
camel
contact
investig
obtain
nasal
swab
serum
sampl
dromedari
camel
found
studi
camel
merscov
polymeras
chain
reaction
pcr
posit
merscov
antibodi
posit
furthermor
full
genom
sequenc
camel
merscov
ident
contact
patient
kasem
et
al
data
suggest
import
role
camel
transmiss
merscov
howev
cohort
patient
laboratoryconfirm
mer
camel
contact
report
patient
deni
patient
report
patient
conzad
et
al
hospitalbas
outbreak
communitybas
cluster
describ
suggest
strongli
humanhuman
transmiss
occur
transmiss
commonli
observ
healthcarebas
outbreak
compar
commun
cluster
number
close
contact
got
infect
patient
confirm
merscov
appear
low
although
evid
patient
spread
infect
disproport
larg
number
individu
super
spreader
hui
phenomenon
clearli
describ
one
outbreak
first
outbreak
identifi
super
spreader
phenomena
korean
outbreak
singl
import
index
case
result
total
case
thought
transmiss
korean
outbreak
link
epidemiolog
five
super
spreader
korea
center
diseas
prevent
phenomenon
also
describ
larg
outbreak
riyadh
saudi
arabia
case
contribut
transmiss
alenazi
et
al
howev
remain
unclear
asymptomat
individu
carri
merscov
transmit
viru
other
first
famili
cluster
report
riyadh
saudi
arabia
three
laboratoryconfirm
case
one
probabl
case
diagnos
two
four
patient
die
studi
investig
index
case
mer
household
contact
secondari
transmiss
rate
found
ci
describ
transmiss
commonli
seen
hospitalbas
outbreak
compar
famili
commun
transmiss
particularli
emerg
depart
ed
clearli
illustr
korean
outbreak
singl
import
case
led
total
case
nosocomi
transmiss
kim
et
al
main
identifi
reason
hospitalsbas
transmiss
overcrowded
ed
late
recognit
suspect
mer
case
inadequ
infect
control
measur
proper
isol
suspect
case
stone
et
al
environment
surfac
hospit
potenti
sourc
transmiss
one
studi
viabl
merscov
detect
surfac
swab
collect
patient
room
restroom
common
corridor
kim
et
al
merscov
sixth
coronaviru
affect
human
lie
within
lineag
c
genu
betacoronaviru
cov
famili
coronavirida
order
nidoviral
close
phylogenet
proxim
two
bat
coronavirus
tylonycteri
bat
cov
pipistrellu
bat
cov
like
coronavirus
envelop
singlestrand
rna
viru
replic
hostcel
cytoplasm
size
rna
genom
approxim
kb
structur
protein
call
e
n
protein
membran
protein
call
spike
protein
play
import
role
viru
attach
entri
host
cell
due
larg
increas
number
diagnos
case
april
concern
merscov
could
undergon
mutat
led
increas
virul
transmiss
viru
howev
assumpt
proven
unlik
drosten
et
al
pathogenesi
histopatholog
merscov
poorli
understood
understudi
postmortem
autopsi
rare
perform
mer
patient
due
cultur
reason
arabian
peninsula
knowledg
histopatholog
merscov
come
vitro
ex
vivo
anim
experi
limit
postmortem
report
male
die
merscov
infect
postmortem
analysi
histopatholog
find
pulmonari
extrapulmonari
tissu
examin
transmiss
electron
microscopi
show
necrot
pneumonia
pulmonari
diffus
alveolar
damag
acut
kidney
injuri
portal
lobular
hepat
myositi
muscl
atroph
chang
brain
heart
histolog
unremark
ultrastructur
viral
particl
local
pneumocyt
pulmonari
macrophag
renal
proxim
tubular
epitheli
cell
macrophag
infiltr
skelet
muscl
alsaad
et
al
begin
outbreak
propos
case
definit
merscov
infect
epidemiolog
purpos
last
updat
juli
unit
state
us
center
diseas
control
prevent
cdc
saudi
ministri
health
moh
develop
case
definit
suspect
confirm
probabl
merscov
infect
tabl
one
earlier
outbreak
saudi
arabia
median
incub
period
merscov
infect
day
ci
day
assiri
et
al
similarli
south
korean
outbreak
median
incub
period
day
percentil
day
korea
center
diseas
prevent
therefor
mer
suspect
patient
present
respiratori
infect
resid
travel
arabian
peninsula
within
last
day
prior
onset
symptom
report
mer
patient
adult
age
group
pediatr
case
report
detect
contact
trace
screen
asymptomat
among
symptomat
case
presenc
comorbid
like
congenit
diseas
commonli
present
altawfiq
et
al
mean
age
one
studi
year
anoth
studi
describ
epidemiolog
clinic
characterist
demograph
merscov
infect
patient
laboratoryconfirm
case
year
age
median
age
year
male
femal
ratio
eighti
nine
percent
patient
requir
icu
admiss
median
time
death
day
rang
day
assiri
et
al
one
studi
saudi
arabia
compar
critic
ill
merscov
patient
critic
ill
nonmerscov
patient
found
merscov
patient
tend
younger
like
requir
mechan
ventil
higher
mortal
eight
report
merscov
infect
pregnanc
jordan
unit
arab
emir
saudi
arabia
three
end
matern
death
begin
epidem
typic
present
report
mer
sever
pneumonia
acut
respiratori
distress
syndrom
ard
without
acut
kidney
injuri
surveil
test
increas
milder
even
asymptomat
case
describ
cohort
patient
merscov
infect
clinic
present
fever
cough
short
breath
myalgia
diarrhea
sore
throat
vomit
abdomin
pain
hemoptysi
assiri
et
al
studi
compar
critic
ill
merscov
infect
patient
critic
ill
patient
nonmer
sever
acut
respiratori
infect
sari
found
mer
patient
younger
nonmer
sari
patient
median
vs
like
male
vs
healthcar
worker
vs
chronic
comorbid
preval
comorbid
mer
sari
nonmer
sari
onset
symptom
merscov
patient
present
er
median
day
admit
icu
day
day
longer
compar
nonmerscov
sari
patient
mechan
ventil
requir
patient
merscov
patient
time
icu
admiss
patient
merscov
like
hypoxem
compar
nonmer
sari
patient
ratio
arteri
oxygen
partial
pressur
fraction
inspir
vs
respiratori
distress
syndrom
direct
epidemiolog
link
laboratoryconfirm
merscov
case
test
merscov
unavail
neg
singl
inadequ
specimen
inconclus
febril
acut
respiratori
ill
clinic
radiolog
histopatholog
evid
pulmonari
parenchym
diseas
eg
pneumonia
acut
respiratori
distress
syndrom
explain
fulli
etiolog
person
resid
travel
middl
east
countri
merscov
known
circul
dromedari
camel
human
infect
recent
occur
test
merscov
inconclus
acut
febril
respiratori
ill
sever
direct
epidemiolog
link
mani
case
mer
present
gastrointestin
manifest
without
respiratori
symptom
among
critic
ill
patient
describ
extrapulmonari
manifest
acut
kidney
injuri
shock
arabi
et
al
patient
report
neurolog
symptom
addit
pneumonia
arabi
et
al
primari
infect
like
sever
oppos
secondari
case
secondari
mer
infect
tend
caus
milder
asymptomat
diseas
howev
sever
diseas
describ
secondari
case
like
younger
comorbid
asymptomat
infect
bee
also
describ
patient
dromedari
camel
contact
identifi
surveil
al
hammadi
et
al
mortal
rate
report
higher
older
age
group
male
gender
patient
comorbid
assiri
et
al
numer
case
mer
occur
among
healthcarework
lead
sever
ill
result
admiss
icu
studi
examin
critic
ill
healthcarework
mer
nurs
physician
comorbid
mainli
chronic
kidney
diseas
fever
present
found
cough
gastrointestin
symptom
eight
healthcar
worker
die
shalhoub
et
al
among
hospit
patient
sever
mer
pneumonia
commonli
observ
laboratori
abnorm
lymphopenia
thrombocytopenia
rais
lactat
dehydrogenas
ldh
abnorm
like
leukopenia
lymphocytosi
rais
aspart
aminotransferas
ast
rais
alanin
aminotransferas
alt
rais
lactat
dehydrogenas
also
observ
assiri
et
al
cohort
critic
ill
merscov
patient
leukopenia
observ
thrombocytopenia
rais
alt
rais
ast
report
symptomat
case
sever
mer
pneumonia
abnorm
chestxray
abnorm
rang
mild
extens
chang
peripher
groundglass
opac
frequent
found
abnorm
cxr
studi
case
da
et
al
find
includ
unilater
bilater
airspac
opac
increas
bronchovascular
mark
patchi
infiltr
interstiti
chang
nodular
opac
reticular
opac
reticulonodular
shadow
pleural
effus
ard
pattern
among
inpati
chest
comput
tomographi
scan
ct
scan
frequent
find
peripher
bibasilar
opac
bilater
patient
present
sever
pneumonia
mer
suspect
base
presenc
epidemiolog
link
resid
travel
arabian
peninsula
especi
histori
contact
camel
contact
person
infect
mer
work
treat
hospit
mer
patient
manag
link
lead
applic
appropri
infect
control
measur
see
initi
diagnost
work
mer
diagnosi
mer
base
posit
realtim
revers
transcriptas
polymeras
chain
reaction
rrtpcr
obtain
respiratori
specimen
nasopharyng
oropharyng
swab
upper
respiratori
tract
often
use
patient
unabl
produc
lower
respiratori
sampl
howev
lower
respiratori
sampl
sputum
endotrach
aspir
bronchoalveolar
lavag
prefer
gener
better
yield
patient
suspect
mer
recommend
send
one
specimen
sinc
neg
test
exclud
diagnosi
cohort
critic
ill
patient
mer
pneumonia
diagnosi
mer
base
sampl
nasopharynx
lower
respiratori
tract
sputum
endotrach
aspir
bronchoalveolar
lavag
diagnosi
establish
first
sampl
patient
second
sampl
patient
repeat
sampl
patient
initi
neg
sampl
collect
posit
one
predominantli
upper
respiratori
tract
sever
serolog
assay
use
includ
enzymelink
immun
sorbent
assay
elisa
immunofluoresc
assay
ifa
typic
use
screen
neutral
techniqu
use
confirm
three
differ
indirect
elisa
develop
valid
base
merscov
nucleocapsid
protein
n
spike
ectodomain
amino
acid
subunit
amino
acid
hashem
et
al
singl
posit
serolog
test
absenc
posit
pcr
consid
probabl
case
set
suspect
merscov
howev
fourfold
increas
merscov
antibodi
titer
neutral
test
consid
confirm
case
viral
pathogen
identifi
critic
ill
patient
mer
pneumonia
includ
coronavirus
respiratori
syncyti
viru
influenza
viru
bacteri
coinfect
describ
critic
ill
patient
mer
pneumonia
acinetobact
speci
pseudomona
speci
klebsiella
pneumonia
staphylococcu
aureu
frequent
isol
specif
antivir
therapi
merscov
infect
date
although
sever
modal
treatment
option
tri
investig
mainstay
manag
merscov
infect
support
care
patient
suspect
sever
mer
pneumoniacov
infect
might
respiratori
pathogen
caus
symptom
therefor
recommend
start
appropri
empir
antimicrobi
therapi
soon
possibl
cover
commun
acquir
nosocomi
associ
pathogen
base
present
commun
hospit
base
local
epidemiolog
guidelin
microbiolog
diagnosi
confirm
support
therapi
mainstay
manag
sever
mer
pneumonia
includ
mechan
ventil
vasopressor
support
renal
replac
therapi
need
oxygen
rescu
therapi
like
extracorpor
membran
oxygen
ecmo
use
patient
refractori
hypoxemia
one
casecontrol
studi
patient
mer
rescu
use
ecmo
compar
match
control
noecmo
associ
reduc
inhospitalmort
compar
alshahrani
et
al
anoth
retrospect
studi
found
critic
ill
healthcar
worker
die
mer
like
receiv
ecmo
probabl
sever
pneumonia
led
use
rescu
therapi
rather
use
ecmo
shalhoub
et
al
corticosteroid
use
frequent
mer
patient
studi
account
timevari
confound
demonstr
corticosteroid
use
associ
differ
mortal
although
associ
prolong
viral
rna
shed
arabi
et
al
data
human
coronavirus
vitro
activ
specif
therapi
use
identifi
potenti
new
therapi
merscov
exampl
includ
combin
ribavirin
interferon
lopinavirritonavir
mycophenol
mofetil
convalesc
plasma
monoclon
polyclon
antibodi
tabl
efficaci
ribavirininterferon
combin
suggest
promis
vitro
anim
experi
cell
cultur
studi
two
cell
viral
cultur
line
grew
merscov
high
concentr
ribavirin
interferon
alpha
b
need
inhibit
viral
replic
drug
use
alon
howev
compar
inhibit
observ
comb
lower
concentr
falzarano
et
al
similar
find
observ
rhesu
macaqu
model
merscov
infect
among
anim
receiv
combin
ribavirin
interferon
alpha
b
hour
inocul
develop
respiratori
symptom
minim
chest
xray
find
infiltr
compar
control
group
also
treat
group
moder
lower
viral
genom
copi
fewer
sever
lung
histopatholog
chang
falzarano
et
al
data
human
base
retrospect
studi
retrospect
cohort
patient
sever
merscov
pneumonia
ribavirin
interferon
combin
therapi
start
median
day
three
diagnosi
show
improv
surviv
compar
patient
receiv
support
therapi
howev
surviv
differ
group
omrani
et
al
retrospect
studi
show
differ
mortal
patient
treat
ribavirin
interferon
combin
patient
receiv
support
therapi
shalhoub
et
al
largest
cohort
studi
adjust
timevari
confound
show
ribavirin
interferon
alpha
beta
associ
differ
mortal
viral
shed
none
patient
receiv
interferon
beta
arabi
et
al
lopinavirritonavir
efficaci
studi
invitro
anim
sever
merscov
infect
show
favor
outcom
chan
et
al
ongo
random
placebo
control
trial
evalu
oral
lopinavirritonavir
combin
subcutan
interferon
hospit
patient
mer
arabi
et
al
use
passiv
immun
therapi
convalesc
plasma
suggest
potenti
therapeut
option
studi
examin
feasibl
convalesc
plasma
therapi
mer
limit
small
pool
donor
suffici
titer
merscov
antibodi
may
relat
shortlast
immun
respons
sever
monoclon
antibodi
prepar
develop
human
bovin
transchromosom
polyclon
antibodi
merscov
develop
undergon
test
phase
trial
beigel
et
al
phase
ii
trial
human
plan
mycophenol
mofetil
efficaci
merscov
suggest
vitro
studi
howev
associ
harm
marmoset
model
chan
et
al
remdesivir
monophosphoramid
prodrug
cadenosin
nucleosid
analog
recent
report
inhibit
sarscov
merscov
batcov
vitro
also
found
therapeut
prophylact
sarscov
infect
mous
modul
agostini
et
al
report
hospitalbas
outbreak
attribut
lack
adher
proper
infect
control
practic
delay
suspect
case
identif
overcrowd
emerg
room
inappropri
triag
address
issu
relat
infect
control
practic
proper
triag
patient
suspect
merscov
result
declin
number
magnitud
hospit
outbreak
us
cdc
publish
guidanc
mer
prevent
healthcar
institut
per
recommend
patient
probabl
confirm
mer
contact
droplet
precaut
eye
protect
patient
airborn
precaut
perform
aerosol
gener
procedur
agp
like
tracheal
intub
bronchoscopi
us
cdc
hand
recommend
contact
airborn
precaut
suspect
confirm
merscov
patient
viral
shed
respiratori
secret
found
least
week
onset
symptom
therefor
isol
precaut
discontinu
neg
pcr
obtain
patient
suspect
confirm
merscov
requir
admiss
isol
home
recommend
avoid
contact
camel
direct
indirect
contact
like
consum
raw
camel
milk
meat
particularli
high
risk
individu
patient
heart
failur
chronic
lung
diseas
immunosuppress
peopl
contact
camel
observ
infect
control
precaut
includ
wash
hand
contact
use
appropri
person
protect
equip
ppe
deal
suspect
confirm
infect
camel
import
note
infect
camel
may
symptomat
might
mild
symptom
saudi
author
made
certain
measur
reduc
camelhuman
transmiss
like
ban
camel
holi
area
move
camel
market
outsid
citi
place
travel
restrict
countri
report
merscov
case
saudi
arabia
laboratoryconfirm
case
report
annual
host
million
muslim
perform
hajj
omrah
pilgrimag
document
relat
case
mer
date
dutch
patient
develop
mer
return
hajj
two
case
thought
acquir
camel
market
raw
milk
consumpt
rather
humanhuman
transmiss
hajj
tabl
summari
treatment
option
merscov
ribavirininterferon
combin
ribavirininterferon
show
efficaci
vitro
rhesu
macaqu
model
data
human
base
retrospect
studi
largest
cohort
account
timevari
confound
demonstr
efficaci
may
differ
efficaci
among
differ
interferon
interferon
lowest
inhibitori
concentr
vitro
falzarano
et
al
falzarano
et
al
lopinavirritonavir
lopinavirritonavir
show
efficaci
vitro
marmoset
model
test
combin
interferon
random
control
trial
merscov
infect
treat
combin
lopinavir
ritonavir
interferon
miracl
chan
et
al
convalesc
plasma
feasibl
option
limit
due
pauciti
donor
arabi
et
al
monoclon
antibodi
sever
monoclon
antibodi
exist
promis
efficaci
vitro
anim
studi
polycolon
antibodi
demonstr
promis
efficaci
vitro
anim
studi
phase
trial
complet
plan
phase
ii
trial
undergo
beigel
et
al
mycophenol
mofetil
efficaci
suggest
vitro
harm
marmoset
model
chan
et
al
remdesivir
new
drug
promis
efficaci
invitro
anim
studi
phase
trial
complet
phase
ii
trial
ongo
ebola
survivor
agostini
et
al
licens
human
vaccin
merscov
till
howev
mani
experiment
candid
vaccin
develop
anoth
approach
vaccin
camel
sourc
infect
mani
human
case
good
progress
made
area
alharbi
end
decemb
global
case
fatal
rate
merscov
infect
report
thought
number
overestim
case
fatal
rate
diseas
milder
asymptomat
case
like
underrepres
report
case
suggest
studi
estim
number
undetect
human
symptomat
case
cauchemez
et
al
cohort
merscov
infect
patient
case
fatal
rate
higher
increas
age
assiri
et
al
anoth
studi
studi
merscov
infect
patient
independ
risk
factor
mortal
age
year
underli
cardiac
comorbid
cancer
healthcar
acquisit
viru
alsahafi
cheng
south
korean
cohort
patient
risk
factor
death
older
age
underli
comorbid
majumd
et
al
